BR112013001939A2 - tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase - Google Patents
tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesteraseInfo
- Publication number
- BR112013001939A2 BR112013001939A2 BR112013001939A BR112013001939A BR112013001939A2 BR 112013001939 A2 BR112013001939 A2 BR 112013001939A2 BR 112013001939 A BR112013001939 A BR 112013001939A BR 112013001939 A BR112013001939 A BR 112013001939A BR 112013001939 A2 BR112013001939 A2 BR 112013001939A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- combination
- nicotinic acid
- receptor agonists
- cognitive disorders
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 229960003512 nicotinic acid Drugs 0.000 title 1
- 239000011664 nicotinic acid Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36767210P | 2010-07-26 | 2010-07-26 | |
| US41191110P | 2010-11-09 | 2010-11-09 | |
| US41235310P | 2010-11-10 | 2010-11-10 | |
| PCT/US2011/045206 WO2012015749A1 (en) | 2010-07-26 | 2011-07-25 | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013001939A2 true BR112013001939A2 (pt) | 2017-07-11 |
Family
ID=44511513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013001939A BR112013001939A2 (pt) | 2010-07-26 | 2011-07-25 | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130225560A1 (pt) |
| EP (1) | EP2598135A1 (pt) |
| JP (1) | JP2014507370A (pt) |
| CN (1) | CN103260619A (pt) |
| BR (1) | BR112013001939A2 (pt) |
| CA (1) | CA2808797A1 (pt) |
| RU (1) | RU2013108223A (pt) |
| TW (1) | TW201210594A (pt) |
| WO (1) | WO2012015749A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| CN107951884A (zh) * | 2017-12-14 | 2018-04-24 | 五邑大学 | 一种氮杂季碳螺环化合物的新用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| PL377777A1 (pl) * | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
| EP1824848A1 (en) | 2004-12-10 | 2007-08-29 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| AU2006295397A1 (en) | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
-
2011
- 2011-07-25 CN CN2011800463455A patent/CN103260619A/zh active Pending
- 2011-07-25 JP JP2013521876A patent/JP2014507370A/ja not_active Withdrawn
- 2011-07-25 RU RU2013108223/15A patent/RU2013108223A/ru unknown
- 2011-07-25 WO PCT/US2011/045206 patent/WO2012015749A1/en active Application Filing
- 2011-07-25 BR BR112013001939A patent/BR112013001939A2/pt not_active IP Right Cessation
- 2011-07-25 EP EP11748786.8A patent/EP2598135A1/en not_active Withdrawn
- 2011-07-25 CA CA2808797A patent/CA2808797A1/en not_active Abandoned
- 2011-07-25 US US13/812,260 patent/US20130225560A1/en not_active Abandoned
- 2011-07-26 TW TW100126456A patent/TW201210594A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2598135A1 (en) | 2013-06-05 |
| US20130225560A1 (en) | 2013-08-29 |
| CN103260619A (zh) | 2013-08-21 |
| CA2808797A1 (en) | 2012-02-02 |
| TW201210594A (en) | 2012-03-16 |
| RU2013108223A (ru) | 2014-09-10 |
| JP2014507370A (ja) | 2014-03-27 |
| WO2012015749A1 (en) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171352T1 (hr) | Wnt-antagonisti i postupci liječenja | |
| BR112012001325A2 (pt) | tratamento de distúrbios do fígado com inibidaores de pi3k | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| RS55071B1 (sr) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
| EP2670434A4 (en) | TREATMENT OF TAUOPATHIA | |
| BRPI1014793A2 (pt) | tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase | |
| BRPI1014775A2 (pt) | tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta | |
| EP2723902A4 (en) | TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND DISEASES | |
| SMT201600412B (it) | Metodi per il trattamento del diabete con antagonisti del dll4 | |
| BR112014000022A2 (pt) | 1-3-tiazepinas ciclopropil-fundidas como inibidores de bace 1 e/ou bace 2 | |
| CO6801718A2 (es) | Composición terapéutica para el tratamiento de glioblastoma | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| DK2925889T3 (da) | Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer | |
| EP2603609A4 (en) | TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND DISORDERS | |
| BR112013015048A2 (pt) | composição para o tratamento de distúrbios metabólicos | |
| AP2014007413A0 (en) | Stable dosage forms of arterolane and piperaquine | |
| BR112013001939A2 (pt) | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase | |
| EP2640378A4 (en) | INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | |
| EP2706854A4 (en) | TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE | |
| IL223385B (en) | Treatment of inflammatory disorders | |
| EP2665488A4 (en) | METHOD AND KITS FOR ASSESSING A PROCAGAGATING HEPARANASE EFFECT, HEPARANASE COMPOSITIONS, AND METHOD FOR TREATING SUFFICIENT INFLAMMATORY CONCUSES | |
| EP2673372A4 (en) | METHODS OF PROGNOSIS AND DELIVERY OF TREATMENT FOR INFLAMMATORY DISORDERS | |
| HK1202459A1 (en) | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders | |
| EP2729184A4 (en) | NEW AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIAN SYSTEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |